Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ipilimumab for metastatic melanoma.
Ozao-Choy J, Carvajal RD, Hamid O. Ozao-Choy J, et al. Among authors: hamid o. Drugs Today (Barc). 2012 Jun;48(6):381-93. doi: 10.1358/dot.2012.48.6.1811777. Drugs Today (Barc). 2012. PMID: 22745924
Selecting patients for KIT inhibition in melanoma.
Carvajal RD, Hamid O, Antonescu CR. Carvajal RD, et al. Among authors: hamid o. Methods Mol Biol. 2014;1102:137-62. doi: 10.1007/978-1-62703-727-3_9. Methods Mol Biol. 2014. PMID: 24258978
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A. Robert C, et al. Among authors: hamid o. Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15. Lancet. 2014. PMID: 25034862 Clinical Trial.
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS. Carvajal RD, et al. Among authors: o day sj, hamid o. Clin Cancer Res. 2015 May 15;21(10):2289-96. doi: 10.1158/1078-0432.CCR-14-1630. Epub 2015 Feb 18. Clin Cancer Res. 2015. PMID: 25695690 Free PMC article. Clinical Trial.
Programmed death 1 immune checkpoint inhibitors.
Trivedi MS, Hoffner B, Winkelmann JL, Abbott ME, Hamid O, Carvajal RD. Trivedi MS, et al. Among authors: hamid o. Clin Adv Hematol Oncol. 2015 Dec;13(12):858-68. Clin Adv Hematol Oncol. 2015. PMID: 27058852 Review.
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.
Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS. Gangadhar TC, et al. Among authors: o day sj, hamid o. J Immunother. 2017 Nov/Dec;40(9):334-340. doi: 10.1097/CJI.0000000000000186. J Immunother. 2017. PMID: 29028788 Free PMC article. Clinical Trial.
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.
D'Angelo SP, Hamid OA, Tarhini A, Schadendorf D, Chmielowski B, Collichio FA, Pavlick AC, Lewis KD, Weil SC, Heyburn J, Schweizer C, O'Shannessy DJ, Carvajal RD. D'Angelo SP, et al. Among authors: o shannessy dj, hamid oa. Invest New Drugs. 2018 Feb;36(1):103-113. doi: 10.1007/s10637-017-0530-4. Epub 2017 Nov 11. Invest New Drugs. 2018. PMID: 29127533 Free PMC article. Clinical Trial.
318 results